Cargando…

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine

Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Here, we investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation, intensive car...

Descripción completa

Detalles Bibliográficos
Autores principales: Govind, Risha, de Freitas, Daniela Fonseca, Pritchard, Megan, Khondoker, Mizanur, Teo, James T., Stewart, Robert, Hayes, Richard D., MacCabe, James H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784620/
https://www.ncbi.nlm.nih.gov/pubmed/35152033
http://dx.doi.org/10.1016/j.euroneuro.2022.01.007
_version_ 1784638781259776000
author Govind, Risha
de Freitas, Daniela Fonseca
Pritchard, Megan
Khondoker, Mizanur
Teo, James T.
Stewart, Robert
Hayes, Richard D.
MacCabe, James H.
author_facet Govind, Risha
de Freitas, Daniela Fonseca
Pritchard, Megan
Khondoker, Mizanur
Teo, James T.
Stewart, Robert
Hayes, Richard D.
MacCabe, James H.
author_sort Govind, Risha
collection PubMed
description Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Here, we investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation, intensive care treatment, and death, amongst patients taking antipsychotics with schizophrenia-spectrum disorders. Using the clinical records of South London and Maudsley NHS Foundation Trust, we identified 157 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders, were taking antipsychotics (clozapine or other antipsychotics) at the time of COVID-19 pandemic in the UK and had a laboratory-confirmed COVID-19 infection. The following health outcomes were measured: COVID-related hospitalisation, COVID-related intensive care treatment and death. We tested associations between clozapine treatment and each outcome using logistic regression models, adjusting for gender, age, ethnicity, neighbourhood deprivation, obesity, smoking status, diabetes, asthma, bronchitis and hypertension using propensity scores. Of the 157 individuals who developed COVID-19 while on antipsychotics (clozapine or other antipsychotics), there were 28% COVID-related hospitalisations, 8% COVID-related intensive care treatments and 8% deaths of any cause during the 28 days follow-up period. amongst those taking clozapine, there were 25% COVID-related hospitalisations, 7% COVID-related intensive care treatments and 7% deaths. In both unadjusted and adjusted analyses, we found no significant association between clozapine and any of the outcomes. Thus, we found no evidence that patients with clozapine treatment at time of COVID-19 infection had increased risk of hospitalisation, intensive care treatment or death, compared to non-clozapine antipsychotic-treated patients. However, further research should be considered in larger samples to confirm this.
format Online
Article
Text
id pubmed-8784620
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-87846202022-01-24 COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine Govind, Risha de Freitas, Daniela Fonseca Pritchard, Megan Khondoker, Mizanur Teo, James T. Stewart, Robert Hayes, Richard D. MacCabe, James H. Eur Neuropsychopharmacol Article Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Here, we investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation, intensive care treatment, and death, amongst patients taking antipsychotics with schizophrenia-spectrum disorders. Using the clinical records of South London and Maudsley NHS Foundation Trust, we identified 157 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders, were taking antipsychotics (clozapine or other antipsychotics) at the time of COVID-19 pandemic in the UK and had a laboratory-confirmed COVID-19 infection. The following health outcomes were measured: COVID-related hospitalisation, COVID-related intensive care treatment and death. We tested associations between clozapine treatment and each outcome using logistic regression models, adjusting for gender, age, ethnicity, neighbourhood deprivation, obesity, smoking status, diabetes, asthma, bronchitis and hypertension using propensity scores. Of the 157 individuals who developed COVID-19 while on antipsychotics (clozapine or other antipsychotics), there were 28% COVID-related hospitalisations, 8% COVID-related intensive care treatments and 8% deaths of any cause during the 28 days follow-up period. amongst those taking clozapine, there were 25% COVID-related hospitalisations, 7% COVID-related intensive care treatments and 7% deaths. In both unadjusted and adjusted analyses, we found no significant association between clozapine and any of the outcomes. Thus, we found no evidence that patients with clozapine treatment at time of COVID-19 infection had increased risk of hospitalisation, intensive care treatment or death, compared to non-clozapine antipsychotic-treated patients. However, further research should be considered in larger samples to confirm this. The Authors. Published by Elsevier B.V. 2022-03 2022-01-24 /pmc/articles/PMC8784620/ /pubmed/35152033 http://dx.doi.org/10.1016/j.euroneuro.2022.01.007 Text en © 2022 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Govind, Risha
de Freitas, Daniela Fonseca
Pritchard, Megan
Khondoker, Mizanur
Teo, James T.
Stewart, Robert
Hayes, Richard D.
MacCabe, James H.
COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
title COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
title_full COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
title_fullStr COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
title_full_unstemmed COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
title_short COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
title_sort covid-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784620/
https://www.ncbi.nlm.nih.gov/pubmed/35152033
http://dx.doi.org/10.1016/j.euroneuro.2022.01.007
work_keys_str_mv AT govindrisha covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT defreitasdanielafonseca covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT pritchardmegan covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT khondokermizanur covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT teojamest covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT stewartrobert covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT hayesrichardd covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine
AT maccabejamesh covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine